MNKD - MannKind Corp Stock Price, Fair Value and News

4.59USD0.00 (0.00%)Market Closed

Market Summary

USD4.590.00

Market Closed

0.00%

MNKD Alerts

Big jump in Revenue (Y/Y)

Big jump in Earnings (Y/Y)

MNKD Stock Price

View Fullscreen

MNKD RSI Chart

MNKD Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

147.28

Price/Sales (Trailing)

5.57

EV/EBITDA

34.92

Price/Free Cashflow

402.81

MNKD Price/Sales (Trailing)

MNKD Profitability

EBT Margin

4.59%

Return on Equity

-3.69%

Return on Assets

1.76%

Free Cashflow Yield

0.25%

MNKD Fundamentals

MNKD Revenue

Revenue (TTM)

224.6M

Rev. Growth (Yr)

63.1%

Rev. Growth (Qtr)

13.32%

MNKD Earnings

Earnings (TTM)

8.5M

Earnings Growth (Yr)

208.52%

Earnings Growth (Qtr)

658.74%

Breaking Down MNKD Revenue

Last 7 days

6.3%

Last 30 days

12.0%

Last 90 days

25.8%

Trailing 12 Months

0.7%

How does MNKD drawdown profile look like?

MNKD Financial Health

Current Ratio

3.84

MNKD Investor Care

Shares Dilution (1Y)

3.03%

Diluted EPS (TTM)

0.04

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	224.6M	0	0	0
2023	128.4M	158.1M	176.5M	199.0M
2022	70.0M	65.6M	76.2M	99.8M
2021	66.3M	74.5M	81.4M	75.4M
2020	61.8M	61.9M	62.7M	65.1M
2019	41.8M	53.0M	63.1M	63.0M
2018	12.2M	13.9M	16.4M	27.9M
2017	134.0M	93.3M	52.5M	11.7M
2016	0	0	131.1M	174.8M
2012	0	0	43.7M	87.4M
2011	82.3K	71.5K	60.8K	50.0K
2010	0	0	0	93.0K

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of MannKind Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 27, 2024	sabella lauren m	sold (taxes)	-79,098	4.63	-17,084	evp chief operating officer
Feb 04, 2024	castagna michael	acquired	99,999	3.27	30,581	chief executive officer
Feb 04, 2024	kay sabrina	acquired	349,998	3.27	107,033	-
Feb 04, 2024	blank burkhard	acquired	499,999	3.27	152,905	evp chief medical officer
Feb 04, 2024	tross stuart a	acquired	49,998	3.27	15,290	chief people & workpl officer
Feb 04, 2024	hooper anthony c	acquired	130,800	3.27	40,000	-
Feb 04, 2024	consiglio ronald j	acquired	81,750	3.27	25,000	-
Feb 04, 2024	sabella lauren m	acquired	49,998	3.27	15,290	evp chief operating officer
Dec 31, 2023	tross stuart a	acquired	3,108	3.09	1,006	chief people & workpl officer
Dec 31, 2023	sabella lauren m	acquired	2,196	3.09	711	evp chief operating officer

Which funds bought or sold MNKD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	VIMA LLC	added	1,900	912	1,640	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-4.76	190,213	1,216,710	-%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-30.22	-201,943	1,332,680	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	reduced	-10.24	432,619	4,126,810	0.03%
May 15, 2024	Cetera Advisor Networks LLC	reduced	-9.98	5,094	47,416	-%
May 15, 2024	Squarepoint Ops LLC	new	-	1,339,990	1,339,990	-%
May 15, 2024	AQR CAPITAL MANAGEMENT LLC	added	3.54	40,084	179,008	-%
May 15, 2024	Steward Partners Investment Advisory, LLC	reduced	-1.39	11,596	62,636	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-64,210	-	-%
May 15, 2024	GTS SECURITIES LLC	reduced	-85.87	-476,397	101,635	-%

Are Funds Buying or Selling MNKD?

Are funds buying MNKD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MNKD

No. of Funds

Unveiling MannKind Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	5.66%	15,248,608	SC 13G/A
Jan 25, 2024	blackrock inc.	8.3%	22,297,032	SC 13G/A
Jan 22, 2024	state street corp	4.80%	12,940,395	SC 13G/A
Feb 09, 2023	vanguard group inc	5.19%	13,664,228	SC 13G/A
Feb 08, 2023	state street corp	6.56%	17,258,797	SC 13G/A
Feb 03, 2023	blackrock inc.	8.0%	21,008,795	SC 13G/A
Feb 10, 2022	state street corp	5.19%	13,048,311	SC 13G
Feb 10, 2022	vanguard group inc	5.03%	12,645,574	SC 13G/A
Feb 01, 2022	blackrock inc.	8.4%	20,993,492	SC 13G/A
Feb 10, 2021	vanguard group inc	5.22%	12,291,714	SC 13G

Recent SEC filings of MannKind Corp

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading

Peers (Alternatives to MannKind Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

MannKind Corp News

Latest updates

MannKind Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	13.3%	66,263,000	58,472,000	51,253,000	48,611,000	40,626,000	36,059,000	32,825,000	18,894,000	11,992,000	12,515,000	22,211,000	23,280,000	17,436,000	18,443,000	15,352,000	15,114,000	16,235,000	15,993,000	14,595,000	15,002,000	17,448,000
Costs and Expenses	-2.1%	49,541,000	50,614,000	46,156,000	46,890,000	46,624,000	48,849,000	42,435,000	39,348,000	33,248,000	36,483,000	28,801,000	33,553,000	23,627,000	42,190,000	24,482,000	23,029,000	23,356,000	27,345,000	23,374,000	25,954,000	30,962,000
Operating Expenses	-	18,598,000	-	-	-	16,213,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
S&GA Expenses	5.2%	11,601,000	11,024,000	13,440,000	14,002,000	13,310,000	11,616,000	13,541,000	15,868,000	12,728,000	-9,162,000	17,221,000	20,056,000	17,413,000	-7,554,000	13,899,000	13,670,000	14,350,000	15,721,000	16,666,000	16,609,000	25,673,000
EBITDA Margin	193.7%	0.13	0.05	-0.07	-0.18	-0.41	-0.69	-1.07	-1.09	-1.16	-0.84	-0.70	-0.89	-	-	-	-	-	-	-	-	-
Interest Expenses	-10.2%	2,567,000	2,858,000	2,815,000	6,873,000	2,424,000	2,997,500	2,812,000	6,642,000	2,371,000	2,769,000	2,803,000	3,180,000	6,452,000	6,259,000	1,057,000	1,084,000	1,071,000	1,021,000	4,126,000	564,000	593,000
Income Taxes	-80.8%	300,000	1,561,000	-	-	-	-	-	-	-	-	-	-	-	-	-218,000	-	-	-	-	-	-
Earnings Before Taxes	267.8%	10,894,000	2,962,000	1,721,000	-5,265,000	-9,795,000	-17,947,000	-14,432,000	-29,023,000	-25,998,000	-28,061,000	-4,426,000	-35,523,000	-12,916,000	-26,411,000	-11,473,000	-10,252,000	-9,322,000	-14,263,000	-10,370,000	-12,387,000	-14,883,000
EBT Margin	188.0%	0.05	-0.05	-0.18	-0.30	-0.55	-0.88	-1.28	-1.33	-1.34	-1.07	-0.97	-1.16	-	-	-	-	-	-	-	-	-
Net Income	658.7%	10,630,000	1,401,000	1,721,000	-5,265,000	-9,795,000	-17,947,000	-14,432,000	-29,023,000	-25,998,000	-28,061,000	-4,426,000	-35,523,000	-12,916,000	-26,411,000	-11,255,000	-10,252,000	-9,322,000	-14,263,000	-10,370,000	-12,387,000	-14,883,000
Net Income Margin	163.0%	0.04	-0.06	-0.18	-0.30	-0.55	-0.88	-1.28	-1.33	-1.34	-1.07	-0.97	-1.16	-	-	-	-	-	-	-	-	-
Free Cashflow	-72.8%	4,295,000	15,804,000	-2,723,000	-14,273,000	-7,155,000	-7,472,000	-28,344,000	-29,148,000	-23,304,000	-17,537,000	-19,430,000	-22,501,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	1.2%	481	475	320	313	298	295	294	286	308	321	238	253	319	109	96.00	103	80.00	94.00	95.00	82.00	101
Current Assets	2.6%	383	373	226	230	223	235	218	193	184	219	159	180	288	79.00	66.00	73.00	49.00	61.00	62.00	50.00	70.00
Cash Equivalents	-19.0%	193	238	83.00	86.00	86.00	70.00	54.00	36.00	67.00	124	52.00	63.00	248	67.00	52.00	63.00	39.00	30.00	30.00	8.00	35.00
Inventory	-7.4%	26.00	29.00	27.00	25.00	22.00	22.00	18.00	21.00	8.00	7.00	7.00	7.00	5.00	5.00	5.00	4.00	3.00	4.00	4.00	4.00	4.00
Net PPE	-0.7%	84.00	84.00	80.00	70.00	55.00	45.00	41.00	38.00	41.00	37.00	31.00	28.00	27.00	26.00	26.00	26.00	27.00	27.00	27.00	27.00	26.00
Goodwill	1.6%	2.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-1.5%	711	721	572	574	554	546	532	533	540	531	423	436	493	289	282	282	278	284	280	278	289
Current Liabilities	-4.1%	100	104	96.00	97.00	82.00	67.00	60.00	60.00	53.00	48.00	50.00	60.00	73.00	74.00	106	68.00	68.00	66.00	64.00	77.00	78.00
Shareholder's Equity	6.6%	-229	-246	-	-	-255	-250	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	0.3%	-3,218	-3,229	-3,230	-3,232	-3,227	-3,217	-3,199	-3,200	-3,156	-3,130	-3,100	-3,097	-3,100	-3,049	-3,022	-3,000	-3,001	-2,991	-2,977	-2,967	-2,954
Additional Paid-In Capital	0.2%	2,986	2,981	2,976	2,969	2,969	2,964	2,960	2,937	2,923	2,918	2,915	2,912	2,886	2,866	2,834	2,829	2,801	2,799	2,791	2,769	2,765
Shares Outstanding	0.3%	271	270	270	268	264	264	255	253	252	249	250	249	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,084	-	-	-	910	-	-	-	1,266	-	-	-	358	-	-	-	194	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-69.1%	6,703	21,678	8,664	2,596	1,156	-2,376	-28,073	-31,982	-18,248	-12,347	-15,184	-21,447	-12,731	235	-13,460	-3,684	-11,219	-5,107	-52,051	-19,728	-11,597
Share Based Compensation	1.9%	3,885	3,813	4,601	5,580	3,655	2,597	3,622	4,422	2,806	3,160	3,179	3,926	1,935	1,904	1,294	2,185	1,128	944	1,640	2,568	999
Cashflow From Investing	-513.5%	-48,437	-7,895	-11,549	3,664	13,792	15,010	27,348	2,022	-39,506	-12,579	4,992	-112,532	-31,418	-4,480	-4.00	-150	19,850	-202	3,761	-1,369	-25,033
Cashflow From Financing	-102.5%	-3,474	141,681	-283	-5,945	1,154	2,825	19,526	-1,776	813	97,370	-590	-51,490	224,977	18,694	2,640	28,188	331	5,042	65,495	-676	3.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MNKD Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Total revenues	$ 66,263	$ 40,626
Expenses:
Cost of goods sold	3,819	5,530
Research and development	10,013	5,605
Selling	11,601	13,310
General and administrative	10,728	10,542
(Gain) loss on foreign currency transaction	(1,399)	954
Total expenses	49,541	46,624
Income (loss) from operations	16,722	(5,998)
Other income (expense):
Interest income, net	3,434	1,302
Interest expense on financing liability	(2,447)	(2,424)
Interest expense	(2,567)	(2,786)
Interest expense on liability for sale of future royalties	(4,248)
Other income		111
Total other expense	(5,828)	(3,797)
Income (loss) before income tax expense	10,894	(9,795)
Income tax expense	264
Net income (loss)	$ 10,630	$ (9,795)
Net income (loss) per share - basic	$ 0.04	$ (0.04)
Weighted average shares used to compute net income (loss) per share - basic	270,356	263,969
Net income (loss) per share - diluted	$ 0.04	$ (0.04)
Weighted average shares used to compute net income (loss) per share - diluted	324,733	263,969
Commercial product sales
Revenues:
Total revenues	$ 18,764	$ 17,562
Collaborations and services
Revenues:
Total revenues	24,848	11,386
Expenses:
Cost of revenue	14,779	10,683
Royalties
Revenues:
Total revenues	$ 22,651	$ 11,678

MNKD Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 193,272	$ 238,480
Short-term investments	107,457	56,619
Accounts receivable, net	19,912	14,901
Inventory	26,442	28,545
Prepaid expenses and other current assets	36,019	34,848
Total current assets	383,102	373,393
Property and equipment, net	83,620	84,220
Goodwill	1,931	1,931
Other intangible asset	1,053	1,073
Long-term investments	3,726	7,155
Other assets	7,447	7,426
Total assets	480,879	475,198
Current liabilities:
Accounts payable	7,149	9,580
Accrued expenses and other current liabilities	42,291	42,036
Financing liability — current	9,872	9,809
Midcap credit facility - current	20,000	20,000
Liability for sale of future royalties - current	10,537	9,756
Deferred revenue — current	7,601	9,085
Recognized loss on purchase commitments — current	2,446	3,859
Total current liabilities	99,896	104,125
Mann Group convertible note	8,829	8,829
Accrued interest - Mann Group convertible note	55	56
Financing liability — long term	94,207	94,319
Midcap credit facility - long term	8,105	13,019
Senior convertible notes	227,214	226,851
Liability for sale of future royalties - long term	137,418	136,054
Recognized loss on purchase commitments — long term	60,287	60,942
Operating lease liability	3,645	3,925
Deferred revenue — long term	67,741	69,794
Milestone liabilities	3,452	3,452
Total liabilities	710,849	721,366
Commitments and contingencies (Note 14)
Stockholders' deficit:
Undesignated preferred stock, $0.01 par value - 10,000,000 shares authorized; no shares issued or outstanding as of March 31, 2024 or December 31, 2023
Common stock, $0.01 par value - 800,000,000 shares authorized; 270,801,781 and 270,034,495 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	2,703	2,700
Additional paid-in capital	2,986,104	2,980,539
Accumulated deficit	(3,218,777)	(3,229,407)
Total stockholders' deficit	(229,970)	(246,168)	$ (255,396)	$ (250,538)
Total liabilities and stockholders' deficit	$ 480,879	$ 475,198

About MannKind Corp

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

CEO	Dr. Michael E. Castagna Pharm.D.
WEBSITE	mannkindcorp.com
INDUSTRY	Biotechnology
EMPLOYEES	391

MannKind Corp Frequently Asked Questions

What is the ticker symbol for MannKind Corp? What does MNKD stand for in stocks?

MNKD is the stock ticker symbol of MannKind Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MannKind Corp (MNKD)?

As of Fri May 17 2024, market cap of MannKind Corp is 1.25 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MNKD stock?

You can check MNKD's fair value in chart for subscribers.

What is the fair value of MNKD stock?

You can check MNKD's fair value in chart for subscribers. The fair value of MannKind Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of MannKind Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MNKD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is MannKind Corp a good stock to buy?

The fair value guage provides a quick view whether MNKD is over valued or under valued. Whether MannKind Corp is cheap or expensive depends on the assumptions which impact MannKind Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MNKD.

What is MannKind Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, MNKD's PE ratio (Price to Earnings) is 147.28 and Price to Sales (PS) ratio is 5.57. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MNKD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MannKind Corp's stock?

In the past 10 years, MannKind Corp has provided -0.19 (multiply by 100 for percentage) rate of return.